Hodgkin Lymphoma

Conference Coverage

Speaker advocates chemo-based salvage in HL

Credit: Rhoda Baer NEW YORK—Physicians should use chemotherapy-based approaches—not brentuximab vedotin—as second-line therapy for recurrent...

Conference Coverage

Brentuximab tops chemo in HL, doc says

NEW YORK—Brentuximab vendotin—not conventional chemotherapy—is the second-line regimen of choice for recurrent Hodgkin lymphoma (HL) patients...